A selective b3-adrenoceptor agonist, mirabegron, an established alternative to antimuscarinic therapy for patients with overactive bladder (OAB), has been shown to induce additional effects against receptors, transporters, and hepatic enzymes.
A selective b3-adrenoceptor agonist, mirabegron, an established alternative to antimuscarinic therapy for patients with overactive bladder (OAB), has been shown to induce additional effects against receptors, transporters, and hepatic enzymes.